Terns CEO Senthil Sundaram resigns for health reasons; Erin Quirk assumes leadership as principal executive officer

Terns Pharmaceuticals, Inc.

Senthil Sundaram resigned as CEO and Board member due to health reasons previously disclosed in January 2022.
Erin Quirk, M.D., President and Head of R&D, assumed leadership effective immediately as principal executive officer.
Sundaram will remain as a Senior Advisor to the company.
Company plans three key clinical data readouts across three programs by end of 2024; balance sheet supports milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.